SunWay Biotech Co., LTD.
SunWay Biotech Co., LTD. focuses on professional research and development, and technical material manufacturing and processing business. The company offers red yeast rice and lactic acid bacteria products, as well as other health supplements; and wholesale and manufacturing of pharmaceutical products. The company also researches, designs, and manufactures Monascus purpureus NTU 568; Lactobacillus… Read more
SunWay Biotech Co., LTD. (1271) - Total Assets
Latest total assets as of June 2025: NT$4.17 Billion TWD
Based on the latest financial reports, SunWay Biotech Co., LTD. (1271) holds total assets worth NT$4.17 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SunWay Biotech Co., LTD. - Total Assets Trend (2019–2024)
This chart illustrates how SunWay Biotech Co., LTD.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
SunWay Biotech Co., LTD. - Asset Composition Analysis
Current Asset Composition (December 2024)
SunWay Biotech Co., LTD.'s total assets of NT$4.17 Billion consist of 21.8% current assets and 78.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 7.7% |
| Accounts Receivable | NT$298.30 Million | 7.9% |
| Inventory | NT$210.03 Million | 5.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$392.16 Million | 10.3% |
| Goodwill | NT$2.03 Billion | 53.4% |
Asset Composition Trend (2019–2024)
This chart illustrates how SunWay Biotech Co., LTD.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SunWay Biotech Co., LTD.'s current assets represent 21.8% of total assets in 2024, a decrease from 70.2% in 2019.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2024, down from 20.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 63.0% of total assets, an increase from 5.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 53.4% of total assets.
SunWay Biotech Co., LTD. Competitors by Total Assets
Key competitors of SunWay Biotech Co., LTD. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
General Mills Inc
NYSE:GIS
|
USA | $32.55 Billion |
|
Maniker F & G Co. Ltd
KQ:195500
|
Korea | ₩123.42 Billion |
|
Xiwang Foodstuffs Co Ltd
SHE:000639
|
China | CN¥6.08 Billion |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
China | CN¥4.57 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥5.88 Billion |
|
Henan Shuanghui Investment & Development Co Ltd
SHE:000895
|
China | CN¥40.64 Billion |
|
Xinjiang Chalkis Co Ltd
SHE:000972
|
China | CN¥1.25 Billion |
|
Daehan Flour Mills Co Ltd
KO:001130
|
Korea | ₩1.61 Trillion |
SunWay Biotech Co., LTD. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - SunWay Biotech Co., LTD. generates 0.26x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, SunWay Biotech Co., LTD. generates $ 3.13 in net profit.
SunWay Biotech Co., LTD. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.93 | 3.57 | 7.95 |
| Quick Ratio | 1.50 | 2.63 | 5.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$575.41 Million | NT$ 595.73 Million | NT$ 287.17 Million |
SunWay Biotech Co., LTD. - Advanced Valuation Insights
This section examines the relationship between SunWay Biotech Co., LTD.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.98 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 3.7% |
| Total Assets | NT$3.79 Billion |
| Market Capitalization | $45.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values SunWay Biotech Co., LTD.'s assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: SunWay Biotech Co., LTD.'s assets grew by 3.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for SunWay Biotech Co., LTD. (2019–2024)
The table below shows the annual total assets of SunWay Biotech Co., LTD. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.79 Billion | +3.75% |
| 2023-12-31 | NT$3.66 Billion | +664.38% |
| 2022-12-31 | NT$478.23 Million | -21.30% |
| 2021-12-31 | NT$607.70 Million | +18.89% |
| 2020-12-31 | NT$511.15 Million | +61.05% |
| 2019-12-31 | NT$317.38 Million | -- |